Ragon Institute of Mass General, MIT, and Harvard
Biana Bernshtein is a Postdoctoral Fellow at the Ragon Institute of MGH, MIT and Harvard, where research focuses on developing and applying systems immunology tools to study antibody-mediated protection against enteric pathogens since September 2020. Prior to this role, Biana was a Postdoctoral Fellow at the Weizmann Institute of Science, working on human cytomegalovirus infection and latency from January 2019 to September 2020. Biana earned a PhD in Immunology from the Weizmann Institute of Science in 2018, completed a Master of Science in Immunology at the same institution in 2013, and obtained a Bachelor of Science in Biology from Tel Aviv University in 2011.
This person is not in the org chart
Ragon Institute of Mass General, MIT, and Harvard
1 followers
The Ragon Institute was established in 2009 with a dual mission: to contribute to the accelerated discovery of an HIV/AIDS vaccine and subsequently establish itself as a world leader in the collaborative study of immunology. Founded with a commitment of $100 million from Phillip T. (Terry) and Susan M. Ragon, and with an additional $200 million gift to endow the Institute announced on April 26, 2019, the Institute is structured and positioned to significantly contribute to a global effort to successfully develop an HIV/AIDS vaccine by: • Creating non-traditional partnerships among experts with different but complementary backgrounds; • Providing a means for rapidly funding promising studies; • Integrating key facets of vaccine development efforts that have tended to follow separate tracks; • Providing a substantial pool of accessible, flexible funding that lowers the threshold for scientists to pursue risky, unconventional avenues of study that are unlikely to attract funding from traditional sources. Such funding encourages innovation, compresses the time it takes to conduct bench-to-bedside research and attracts new minds to the field. The Ragon Institute creates a singular opportunity and environment to engage scientists, engineers and clinicians in challenging research for which there is no greater benefit – saving lives and curing the ill.